iSBTc 19th Annual Meeting

Some presentations are available for viewing. Please select the icon to view a presentation.

Friday, November 5, 2004
7:55 am - 8:15 am Welcome Address
Steven Hirschfeld, MD, PhD
FDA Office of Cellular, Tissue and Gene Therapies
8:15 am - 9:00 am Keynote Address
Design and Selection of Vaccine Adjuvants

Carl Alving, MD
Walter Reed Army Institute of Research
9:00 am - 11:45 am Plenary Session: Immune Adjuvants
Chair(s)
Eli Gilboa, PhD
Duke University Medical Center
Donald L. Morton, MD
John Wayne Cancer Institute
9:00 am - 9:30 am Immunomodulation of Cellular and Humoral Responses During Active Immunotherapy for Melanoma
Donald L. Morton, MD
John Wayne Cancer Institute
9:30 am - 10:00 am Immunological Adjuvants, the Indispensable Third Component
Philip O. Livingston, MD
Memorial Sloan-Kettering Cancer Center
10:00 am - 10:15 am Regression of Established Autochthonous Mammary Tumors and Induction of Systemic Anti-Tumor T- and B-Cell Immunity in HER-2/NEU Transgenic Mice after Treatment with IL-12 and GM-CSF-Encapsulated Microspheres
Nejat Egilmez, PhD
J.G. Brown Cancer Center
10:15 am - 10:30 am Induction of TH1-Type Immunity and Tumor Protection with a Prostate Specific Antigen DNA Vaccine and pIL-18 Adjuvant Therapy
Deborah J. Marshall, PhD
Centocor, Inc.
11:00 am - 11:15 am Adjuvant Effect of Topical Imiquimod Compared to Intradermal GM-CSF on the Cellular Composition of Draining Lymph Nodes
Wolfgang M. Wagner, PhD
University of Washington
11:15 am - 11:45 am Therapeutic Vaccination with mRNA Transfected Dendritic Cells Eli Gilboa, PhD
Duke University Medical Center
11:45 am - 1:00 pm Odd Number Poster Presentations/Box Lunches
1:00 pm - 3:00 pm Plenary Session: Adoptive Immunotherapy
Chair(s)
Bernard A. Fox, PhD
Earle A. Chiles Research Institute
Patrick Hwu, MD
MD Anderson Cancer Center
1:00 pm - 1:15 pm Adoptive Immunotherapy of Cancer with Polyclonal Hyperexpanded CD4 and CD8 T Cells Derived from Tumor-Draining Lymph Nodes
Gregory E. Plautz, MD
Cleveland Clinic Foundation
1:15 pm - 1:30 pm Therapeutic Efficacy of MUC1-Specific Cytotoxic T Lymphocytes and CD137 Co-Stimulation in a Spontaneous Mammary Cancer Model
Pinku Mukherjee, PhD
Mayo Clinic Scottsdale
1:30 pm - 2:00 pm Enhanced Antitumor Effects Using Dendritic Cells to Stimulate Adoptively Transferred T Cells In Vivo Patrick Hwu, MD
MD Anderson Cancer Center
2:00 pm - 2:30 pm Tumor Antigen Immunization of Human Allotransplant Donors in Myeloma
Larry Kwak, MD, PhD
MD Anderson Cancer Center
2:30 pm - 3:00 pm Exploiting Lymphopenia to Reboot the Immune Response to Cancer
Bernard A. Fox, PhD
Earle A. Chiles Research Institute
3:15 pm - 5:30 pm Concurrent Session I: Cancer Biometrics Review
Chair(s)
Michael T. Lotze, MD
University of Pittsburgh School of Medicine
George Coukos, MD, PhD
University of Pennsylvania Medical Center
3:15 pm - 3:30 pm Wheres the Rub Really Useful Biomarkers in Cancer
Michael T. Lotze, MD
University of Pittsburgh School of Medicine
3:30 pm - 4:00 pm Clinical Proteomics: Applications at the Bedside
Julia Wulfkuhle, MD
Division of Therapeutic Products/CBER/FDA
4:00 pm - 4:30 pm Bioinformatical Data Reduction Approaches for High Dimensional Data Derived from High Throughput Assays
Yu Shyr, MD

Vanderbilt University School of Medicine
4:30 pm - 4:45 pm Flow Cytometric Monitoring of Jak-STAT Signal Transduction Within Melanoma Cells
Gregory B. Lesinski, PhD The Ohio State University
4:45 pm - 5:00 pm Characterizing Complete Responders to IL-2 Using Gene Expression Analysis and Tissue Array Validation in Patients with Metastatic Renal Cell Carcinoma
Allan Pantuck, MD
University of California Los Angeles
5:00 pm - 5:15 pm Gene Expression Patterns Associated with Renal Cancer (RCC) Response and Resistance to IL-2-Based Therapy
Philip G. Febbo, MD
Duke Institute for Genome Science and Policy
5:15 pm - 5:30 pm Markers from the Tumor Microenvironment. Are They Useful? George Coukos, MD, PhD
University of Pennsylvania Medical Center
3:30 pm - 5:15 pm Concurrent Session II: Dendritic Cells and Vaccines
Chair(s)
Craig L. Slingluff, Jr., MD
University of Virginia
Jeffrey S. Weber, MD, PhD
University of Southern California Norris Cancer Center
3:30 pm - 3:45 pm Dacarbacine (DTIC) Versus Vaccination with Autologous Peptide-Pulsed Dendritic Cells (DC) in First-Line Treatment of Patients with Metastatic Melanoma: Results of a Multicenter Prospective Randomized Phase III Study
Dirk Schadendorf, MD
German Cancer Research Center
3:45 pm - 4:00 pm Strategies to Augment the Efficacy of Dendritic Cell-Based Vaccines
Johannes Vieweg, MD FACS
Duke University
4:00 pm - 4:15 pm Invited Speaker Q&A
4:15 pm - 4:30 pm Treatment of Metastatic Colorectal Cancer Patients with a Tumor Lysate Pulsed Dendritic Cell Vaccine: A Randomized Evaluation of Ex Vivo CD40L Activation
Richard J. Barth, Jr., MD
Dartmouth-Hitchcock Medical Center
4:30 pm - 4:45 pm A Randomized Placebo-Controlled Phase II Study with the Cancer Vaccine IGN101 in Patients with Epithelial Cancers
Marc Salzberg
Pharma Brains, Ltd.
4:45 pm - 5:00 pm Vaccination of Patients with Recurrent AML with WT1-Peptide Induces Clinical and Molecular Remissions as Well as Specific Memory and Effector T Cells in Perhipheral Blood and Bone Marrow
Anne Letsch, MD
Charit Campus Benjamin Franklin
5:00 pm - 5:15 pm Multipeptide Vaccines for Melanoma: Strategies for Increasing the Breadth of the T Cell Repertoire
Craig L. Slingluff, Jr., MD
University of Virginia
Saturday, November 6, 2004
8:15 am - 9:00 am Keynote Address
Regulatory T Cells: Friend or Foe
Ethan Shevach, MD National Institutes of Health
9:00 am - 11:45 am Plenary Session: Mechanisms of Escape/Resistance
Chair(s)
Thomas Gajewski, MD, PhD
University of Chicago Medical School
David Munn, MD
Medical College of Georgia
9:00 am - 9:15 am Cross Resistance of Melanoma Cells to Apoptosis Induced by Trail and Chemotherapy
Peter Hersey, MD, PhD
Newcastle Mater Hospital
9:15 am - 9:30 am MYCN Regulates CCL2/MCP-1 Production in Neuroblastoma Cells: A Mechanism of Tumor Escape and a Target for Immunotherapy
Liping Song, PhD
Childrens Hospital Los Angeles
9:30 am - 10:00 am Mechanisms of Resistance to Anti-Tumor Immunity Downstream from Initial T Cell Priming
Thomas Gajewski, MD, PhD
University of Chicago Medical School
10:00 am - 10:15 am Melanoma Gene Expression Profiles To Identify Mechanisms of Tumor Resistance to a Multi-Peptide/IL-12 Vaccine
Helena A. Harlin, PhD
University of Chicago
10:45 am - 11:15 am Tryptophan Catabolism and Tumor Immune Evasion
David Munn, MD
Medical College of Georgia
11:15 am - 11:45 am Changing Battlefields: Bring Immune Response Into Tumor Site
Yang-Xin Fu, MD, PhD
University of Chicago
11:45 am - 1:00 pm Even Number Poster Presentations/Box Lunches
1:00 pm - 2:20 pm Plenary Session: iSBTc Presidential Session
Chair
Michael B. Atkins, MD
Beth Israel Deaconess Medical Center
1:00 pm - 1:20 pm Tumor-Infiltrating Dendritic Cell Precursors Recruited by a β-Defensin Contribute to Vasculogenesis Under the Influence of VEGF-A in Ovarian Cancer
Jose Ramon Conejo-Garcia, MD, PhD
University of Pennsylvania
1:20 pm - 1:40 pm Imiquimod Treatment In Vivo Induces Massive Skin Recruitment and Activation of Plasmacytoid Dendritic Cells in a Disease-Independent Manner
Mirjana Urosevic, MD
University Hospital Zurich
1:40 pm - 2:00 pm CpG in the Immunotherapy of B Cell Lymphoma in an Animal Model
Jiali Li, PhD (Presidential Award Winner)
Stanford University
2:00 pm - 2:20 pm Acquisition of Terminal Effector Functions In Vitro Impairs In Vivo Anti- Tumor Efficacy
Luca Gattinoni, MD (Presidential Award Winner)
National Cancer Institute - Surgery Branch
2:30 pm - 4:00 pm Concurrent Session I: Poster Presentations 2:30 pm - 3:15 pm   Odd Number Poster Session
3:15 pm - 4:00 pm   Even Number Poster Session
2:45 pm - 4:15 pm Concurrent Session II: Cytokines
Chair(s)
Jared A. Gollob, MD
Duke University Medical Center
Steven Dubinett, MD
University of California Los Angeles Lung Cancer Research Program
2:45 pm - 3:15 pm Cyclooxygenase-2 Regulates Cytokine Balance and Apoptosis Resistance in Non-Small Cell Lung Cancer
Steven Dubinett, MD
University of California Los Angeles Lung Cancer Research Program
3:15 am - 3:30 pm Expression of CXC Chemokines During IL-2 Therapy Correlates with Response in Metastatic Renal Cell Carcinoma
Karen Riedl, MD
University of California Los Angeles, David Geffen School of Medicine
3:30 pm - 3:45 pm Grade 4 Thrombocytopenia During Treatment with High-Dose Interleukin-2 Is a Predictor of Response in Melanoma But Not in Renal Cell Cancer
Timothy E. Bael, MD
Duke University Medical Center
3:45 pm - 4:15 pm Use of DNA Microarray Analysis to Identify Genes and Signaling Pathways Central to the Anti-Melanoma Effect of Interferon-
Jared A. Gollob, MD
Duke University Medical Center
4:00 pm - 5:00 pm Poster Discussion Session I
4:00 pm - 4:20 pm Discussion on Dendritic Cells and Vaccines
Howard L. Kaufman, MD
New York Presbyterian Hospital -Columbia Campus
4:20 pm - 4:35 pm Discussion on Mechanisms of Escape/Resistance
James W. Mier, MD
Beth Israel Deaconess Medical Center
4:35 pm - 4:50 pm Discussion on Adoptive Immunotherapy
James W. Young, MD
Memorial Sloan-Kettering Cancer Center
4:50 pm - 5:00 pm General Discussion
4:30 pm - 5:00 pm Poster Discussion Session II
4:30 pm - 4:45 pm Discussion on Antibody Therapy
George J. Weiner, MD
University of Iowa
4:45 pm - 5:00 pm Discussion on Natural Killer Cells & Innate Immunity
Theresa L. Whiteside, PhD
University of Pittsburgh Cancer Institute
Sunday, November 7, 2004
8:00 am - 11:00 am Plenary Session: New Agents in Development - Sponsored by Antigenics
Chair(s)
Steven J. ODay, MD
John Wayne Cancer Center
Gary R. Jones, MD
Berlex Laboratories
8:00 am - 8:30 am Epigenetic Therapy
Peter Jones, PhD
University of Southern California Norris Comprehensive Cancer Center
8:30 am - 8:45 am Heat Shock Protein-Based Immunotherapy of Cancer
Alem Truneh, PhD
Antigenics, Inc.
8:45 am - 9:15 am Interleukin-21 Elicits Durable T and NK Cytotoxicity: Basic Biology to Clinical Trials
Pallavur V. Sivakumar, PhD
Zymogenetics, Inc.
9:15 am - 9:30 am Threshold of Credibility: A New Approach to Product Development for Metastatic Melanoma Therapy
Steven Hirschfeld, MD, PhD
FDA Office of Cellular, Tissue and Gene Therapies
9:30 am - 9:45 am T-Cell Independent Activity of Talabostat (PT-100) Against Human Tumor Xenografts in Mice
Barry Jones, PhD
Point Therapeutics
9:45 am - 10:00 am AME-133: A Next-Generation Anti-CD20 Engineered for Enhanced Killer Function
James B. Breitmeyer, MD, PhD
Applied Molecular Evolution, Inc.
10:00 am - 10:15 am Enhancement of Anti-Tumor Efficacy of Paclitaxel by CpG ODN; TLR9 Agonist in Metastatic Murine Cancer Models
Risini D. Weeratna, PhD
Coley Pharmaceutical Group
10:15 am - 10:30 am Therapeutic Efficacy of Gc Protein-Derived Macrophage Activating Factor (GcMAF) for Adenocarcinoma
Nobuto Yamamoto, PhD
Socrates Institute for Therapeutic Immunology
10:30 am - 10:45 am A Phase I Trial of Immunocytokine HU14.18-IL2 in Children with Recurrent or Refractory Neuroblastoma and Other GD2 Positive Malignancies: A Study of the Childrens Oncology Group Kaci L. Osenga, MD
University of Wisconsin Comprehensive Cancer Center
10:45 am - 11:00 am Proteasome Inhibition To Maximize the Apoptotic Potential of Cytokine Therapy for Murine Neuroblastoma Tumors
Tahira Khan, PhD
National Cancer Institute

Creative Commons License
All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.